Dishman carbogen bonds: price, ISIN, YTM, rating & key risks

Quick Overview

Dishman Carbogen Amcis Limited (DCAL) is a fully integrated, global pharmaceutical partner specializing in Contract Research and Manufacturing Services (CRAMS) and Contract Development and Manufacturing Organization (CDMO) solutions. Headquartered in Ahmedabad, Gujarat, the multinational corporation operates 10 state-of-the-art manufacturing facilities spanning India, Switzerland, France, the Netherlands, the UK, and China. The firm supports global life science and biotechnology majors through the entire drug lifecycle from early-stage molecule discovery to commercial Active Pharmaceutical Ingredient (API) production. To optimize its long-term capital reserves and fund strategic international infrastructure, the enterprise actively issues Non-Convertible Debentures (NCDs) to institutional and private fixed-income markets.

This analytical report evaluates two widely tracked primary and secondary fixed-income assets: ISIN INE385W07067 and ISIN INE385W07059. Structured as senior secured debt instruments with a fixed 10.00% annual coupon rate paid via quarterly distribution cycles, these Dishman carbogen bonds feature maturity dates mapped to December 2027 and January 2029, respectively. Assigned a credit rating profile of IND A / Negative by India Ratings and Research, these debentures present an attractive option for fixed-income allocators seeking higher yield premiums over standard banking fixed deposits.

What Is Dishman Carbogen Amcis Limited?

Originating in 1983 under visionary promoter leadership, Dishman Carbogen Amcis Limited has grown into an international pharmaceutical contract manufacturing powerhouse. The corporation operates across two core commercial segments:

• Contract Research and Manufacturing Services (CRAMS): Generating approximately 84% of total group revenues, this division collaborates with multi-national pharmaceutical clients on New Chemical Entities (NCEs), high-potency APIs (HPAPIs), and clinical trial drug development batches.

• Marketable Molecules & Quaternary Ammonium Compounds (Quats): Accounting for the remaining revenue share, this business segment manufactures commercial phase APIs, disinfectants, and specialty chemical intermediates sold directly to global healthcare and industrial processing markets.

By maintaining specialized high-potency containment facilities in Europe and cost-efficient large-scale commercial plants in India (such as its primary manufacturing site at Bavla, Gujarat), DCAL provides clients with end-to-end drug supply security.

Dishman Carbogen Bonds: Key Technical Specifications

Fixed-income participants evaluating specialized pharmaceutical credit metrics must examine the core structural parameters of each debenture tranche. The comparative table below outlines the verified attributes for both key ISINs:

*Note: Secondary market metrics like clean purchase prices, accrued interest, and Yield to Maturity (YTM) fluctuate dynamically based on macroeconomic rate policies and market trading volumes.

Deep-Dive Analysis: ISIN INE385W07067 & INE385W07059

Tranche 1: ISIN INE385W07067 (Maturity December 2027)

The Dishman carbogen amcis NCD tranche registered under ISIN INE385W07067 serves as a medium-duration capital allocation instrument. Expiring in December 2027, it offers a remaining duration lifecycle that limits portfolio exposure to long-term interest rate shifts. Featuring a contractual 10.00% annual coupon rate paid in quarterly installments, this bond provides predictable cash flows for fixed-income portfolios.

Tranche 2: ISIN INE385W07059 (Maturity January 2029)

For allocators aiming to lock in double-digit coupon rates over a longer horizon, ISIN INE385W07059 extends principal maturity outward to January 20, 2029. It carries the same 10.00% annual coupon rate distributed quarterly. Depending on the specific issue series terms, this tranche may feature an amortizing principal repayment schedule alongside quarterly interest payouts, reducing outstanding credit exposure as the bond approaches maturity.

Secondary Traded Price vs Yield to Maturity (YTM)

Understanding how secondary market prices impact absolute Yield to Maturity (YTM) is essential for corporate bond investors.

• The Contractual Coupon Baseline: The fixed benchmark. Locked firmly at 10.00% per annum on the Rs 1,00,000 face value, it mandates that the issuer distribute Rs 2,500 per unit during each quarterly payout cycle.

• Discounted Secondary Price Action: When bonds trade on secondary exchange platforms, market prices fluctuate based on broader interest rates and company-specific rating updates. If units trade at a discount below nominal face value (e.g., around ~Rs 91,660 to Rs 98,500 per unit), the buyer's effective yield increases.

• Yield Enhancement Mechanics: Purchasing debenture units below face value elevates total returns. Beyond collecting the regular 10.00% coupon payouts, the investor realizes a capital gain when the bond matures back to its full face value. This price discount pushes the effective secondary market YTM into the ~11.00% to 11.70% range.

Credit Rating Safety Validation: What IND A / Negative Means

The long-term bond programs of Dishman Carbogen Amcis Limited hold an assigned credit rating of IND A / Negative from India Ratings and Research.

[AAA Tier: Highest Safety] -> [AA Tier: High Safety] -> [IND A / Negative (Current Adequate Safety Tier)] -> [BBB Floor]

Instruments positioned within the "A" tier are defined as possessing an adequate degree of safety regarding the timely servicing of financial commitments, with low to moderate baseline credit risk.

Rationale for the Negative Outlook

Credit rating agencies revised the rating outlook to Negative following operational margin compression, working capital expansions, and elevated net adjusted debt leverage (exceeding 3.0x net debt-to-EBITDA) during recent capital expenditure cycles. However, the company maintains adequate liquidity reserves—including substantial cash balances and liquid reserves to comfortably service upcoming debt obligations.

Senior Secured Collateral Structure

To protect debenture holders, these issues are structured as Senior Secured NCDs. The debentures are secured by a fixed charge over designated manufacturing assets, real estate property, and lien-marked fixed deposits, providing a minimum 1.10x security cover ratio supervised by the appointed debenture trustee. In an insolvency scenario, senior secured bondholders hold priority recovery rights over unsecured creditors and equity investors.

Financial Snapshot & CRAMS Operational Scale

Evaluating the credit risk of a global pharmaceutical manufacturer requires examining key financial indicators:

• Substantial Revenue Base: DCAL generates annual consolidated revenues exceeding Rs 2,600 crore to Rs 2,800 crore, reflecting its established market presence in global drug development.

• Healthy Operating EBITDA: The group delivers annual operating EBITDA of over Rs 400 crore to Rs 450 crore, driven by high-margin CRAMS contracts.

• Diversified Global Infrastructure: With manufacturing plants inspected and approved by major international regulatory bodies—including the US FDA, European EDQM, and Japanese PMDA—the firm maintains strict quality standards required for global API supply.

• Robust Client Relationships: The company's CRAMS segment maintains long-term partnerships with leading global pharmaceutical corporations, maintaining a strong pipeline of active drug candidates in phase-II and phase-III clinical trials.

Key Risks of Investing in Dishman Carbogen NCDs

While double-digit yields offer attractive income potential, investors should evaluate several structural risk factors:

• Elevated Debt Leverage & Margin Sensitivity: Adjusted net leverage metrics remain above 3.0x EBITDA. Delays in ramping up commercial production or unexpected margin pressure could slow debt reduction efforts.

• Extended Working Capital Cycles: Operating in the global CRAMS sector requires maintaining high inventory levels of complex chemical intermediates, stretching working capital cycles to around 180 days.

• Strict Regulatory Oversight: Pharmaceutical facilities face ongoing compliance audits from agencies like the US FDA and EDQM. Import alerts or regulatory observations at major manufacturing sites can temporarily disrupt revenue generation.

• Secondary Market Liquidity Limits: Although listed on the BSE debt segment, private placement NCD tranches can see low daily trading volumes. Investors seeking to sell prior to maturity should account for potential bid-ask spread variations.

Taxation Framework on Indian Corporate NCDs

Earnings from listed corporate debentures are taxed under the Indian Income Tax Act as follows:

1. Taxation on Quarterly Interest Payouts: Recurring 10.00% coupon distributions are classified under Income from Other Sources and taxed at the investor's applicable individual income tax slab rate.

2. Tax Deducted at Source (TDS): Pursuant to Section 193 of the Income Tax Act, a mandatory 10% TDS deduction applies at the time of interest payment. Investors can claim this deduction as a tax credit when filing their annual income tax returns (ITR).

3. Capital Gains on Secondary Market Sales: If debentures are sold on an exchange before maturity:

○ Holding Period Under 12 Months: Treated as Short-Term Capital Gains (STCG) and taxed at individual tax slab rates.

○ Holding Period Over 12 Months: Treated as Long-Term Capital Gains (LTCG) and taxed at a flat rate of 12.5% without indexation benefits under current tax laws.

Investor Evaluation Checklist Before Allocation

Before finalizing a bond allocation on an online corporate debt platform, verify these key metrics:

• Confirm the Target ISIN: Ensure the code matches INE385W07067 or INE385W07059 depending on your preferred maturity date (2027 vs. 2029).

• Review Clean vs. Dirty Price Quotes: Check whether the secondary listing quote includes accrued interest accumulated since the last quarterly payout.

• Assess Quarterly Cash Flow Alignment: Confirm that a quarterly interest distribution schedule fits your cash management objectives.

• Apply Asset Allocation Limits: Diversify your portfolio by limiting allocations to A-rated corporate debt to a prudent percentage of your overall fixed-income holdings.

FAQs

What is the specific instrument structure of ISIN INE385W07067 and INE385W07059?

Both Dishman Carbogen bonds are structured as senior secured, exchange-listed Non-Convertible Debentures (NCDs) offering a 10.00% annual coupon rate paid quarterly. ISIN INE385W07067 matures in December 2027, while ISIN INE385W07059 matures in January 2029.

What is the core business focus of Dishman Carbogen Amcis Limited?

The enterprise operates as a global pharmaceutical CRAMS and CDMO player, providing contract drug development, high-potency API synthesis, and commercial manufacturing services to global life sciences companies.

What does the assigned credit rating of IND A / Negative indicate?

An IND A / Negative rating from India Ratings indicates an adequate degree of safety regarding debt servicing, carrying low to moderate credit risk. The Negative outlook reflects elevated leverage and working capital requirements.

How frequently is interest paid on these debenture issues?

Interest distributions for both ISIN INE385W07067 and ISIN INE385W07059 are processed on a quarterly frequency on designated payment dates until final maturity.

Where can investors track live pricing and trade listed Dishman Carbogen bonds?

Fixed-income investors can review clean/dirty prices, verify complete term sheets, and trade listed corporate bonds through digital screens on the OBPP Platforms like BondScanner

Published By

BondScanner, a SEBI-registered Online Bond Platform Provider (OBPP). Links to BondScanner's bond listing page, Android app, and iOS app referenced in this article are for informational purposes only.

Explore listed bonds on the BondScanner app:

Disclaimer

This blog is intended solely for educational and informational purposes. The instruments, issuer categories, yield ranges and examples mentioned herein are illustrative and should not be construed as investment advice or recommendations.

BondScanner is a SEBI-registered OBPP and does not provide personalised investment advice. Nothing in this article is a solicitation to buy or sell any security. Investments in debt securities are subject to risks, including delay and/or default in payment. Investors must read all offer-related documents carefully before investing.